STELARA (Janssen-Cilag Pty Ltd)
Product name
STELARA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
214 working days (255)
Active ingredients
ustekinumab
Registration type
EOI
Indication
Ulcerative colitis
STELARA (solution for injection) is now also indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.